Joseph Schwartz analyst LEERINK

Currently out of the existing stock ratings of Joseph Schwartz, 46 are a HOLD (18.93%), 191 are a BUY (78.6%), 6 are a SELL (2.47%).

Joseph Schwartz

Work Performance Price Targets & Ratings Chart

Analyst Joseph Schwartz, currently employed at LEERINK, carries an average stock price target met ratio of 56.73% that have a potential upside of 51.67% achieved within 333 days.

Joseph Schwartz’s has documented 488 price targets and ratings displayed on 44 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TVTX, Travere Therapeutics at 11-Oct-2024.

Wall Street Analyst Joseph Schwartz

Analyst best performing recommendations are on LRMR (LARIMAR THERAPEUTICS).
The best stock recommendation documented was for LRMR (LARIMAR THERAPEUTICS) at 12/1/2015. The price target of $132 was fulfilled within 1 day with a profit of $59.16 (30.95%) receiving and performance score of 309.48.

Average potential price target upside

AMAG AMAG Pharmaceuticals ARNA Arena Pharmaceuticals ASND Ascendis Pharma AS AUPH Aurinia Pharmaceuticals BMRN Biomarin Pharmaceutical CCXI ChemoCentryx FOLD Amicus Therapeutics ICPT Intercept Pharmaceuticals MDCO The Medicines Company PTGX Protagonist Therapeutics QURE Uniqure NV RARE Ultragenyx SLDB Solid Biosciences LLC SPRB Spruce Biosciences  SRPT Sarepta Therapeutics AMTI Applied Molecular Transport  BIIB Biogen CBAY Cymabay Therapeu ACHN Achillion Pharmaceuticals EWTX Edgewise Therapeutics GOSS Gossamer Bio IFRX InflaRx N.V. IMRA Imara INSM Insmed ONCE Spark Therapeutics RETA Reata Pharmaceuticals RPHM Reneo Pharmaceuticals BOLD Audentes Therapeutics DSGN Design Therapeutics PHVS Pharvaris BV RNA Avidity Biosciences  TVTX Travere Therapeutics UTHR United Therapeutics ZFGN Zafgen KALV Kalvista Pharmaceuticals REGN Regeneron Pharmaceuticals SYBX Synlogic ALDR Alder BioPharmaceuticals CRNX Crinetics Pharmaceuticals KDNY Chinook Therapeutics PTI Proteostasis Therapeutics RTRX Travere Therapeutics ANTX AN2 Therapeutics LRMR Larimar Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$13.75

$14

4 years 1 months 28 days ago
(05-Oct-2020)

13/18 (72.22%)

$0.67 (5.12%)

50

Buy

$13.75

$14

4 years 2 months 1 days ago
(02-Oct-2020)

5/7 (71.43%)

$0.01 (0.07%)

130

Hold

$10

$-3.75 (-27.27%)

$13

4 years 3 months 15 days ago
(18-Aug-2020)

6/8 (75%)

$-0.63 (-5.93%)

126

Buy

$10

$-3.75 (-27.27%)

$14

4 years 3 months 15 days ago
(18-Aug-2020)

1/5 (20%)

$-0.63 (-5.93%)

6

Hold

4 years 3 months 26 days ago
(07-Aug-2020)

0/3 (0%)

$17.19 (61.81%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Joseph Schwartz is most bullish on?

Potential upside of $21.19 has been obtained for TVTX (TRAVERE THERAPEUTICS)

Which stock is Joseph Schwartz is most reserved on?

Potential downside of -$0 has been obtained for ANTX (AN2 THERAPEUTICS)

What Year was the first public recommendation made by Joseph Schwartz?

On 2008

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?